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Abstract
Background: Healthcare-Associated Infections (HAIs) represent one of the leading issues to patient safety as well as
a significant economic burden. Similarly, Antimicrobial Use (AMU) and Resistance (AMR) represent a growing threat
to global public health and the sustainability of healthcare services.
Methods: A Point Prevalence Survey (PPS) following the 2016 ECDC protocol for HAI prevalence and AMU was
conducted at Ferrara University Hospital (FUH). Data were collected by a team of trained independent surveyors in
2016 and 2018. Risk factors independently associated with HAI were assessed by a multivariate logistic regression
model.
Results: Of the 1102 patients surveyed, 115 (10.4%) had an active HAI and 487 (44.2%) were on at least 1 systemic
antimicrobial agent. Factors independently associated with increased HAI risk were a “Rapidly Fatal” McCabe score
(expected fatal outcome within 1 year), presence of medical devices (PVC, CVC, indwelling urinary catheter or
mechanically assisted ventilation) and a length of hospital stay of at least 1 week. The most frequent types of HAI
were pneumonia, bloodstream infections, and urinary tract infections. Antimicrobial resistance to third-generation
cephalosporins was observed in about 60% of Enterobacteriaceae.
Conclusions: The survey reports a high prevalence of HAI and AMU in FUH. Repeated PPSs are useful to control
HAIs and AMU in large acute-care hospitals, highlighting the main problematic factors and allowing planning for
improvement actions.
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Point prevalence survey
Background
Healthcare-associated infections (HAIs) represent one of
the leading issues to patient safety as well as a significant
economic burden on healthcare systems [1].
About 3.2 million HAIs occur every year in the European
Union (EU) [2], causing 37,000 deaths as a direct conse-
quence [3], over 2.5 million Disability Adjusted Life Years
(DALYs) [4] and 16 million extra days of hospitalization, with
an approximate cost of around 7 billion euros [3]. In 2016,
the European Centre for Disease Prevention and Control
(ECDC) estimated that the burden of six most frequent types
of HAI (pneumonia, urinary tract infection – UTI, surgical
site infection, Clostridium difficile infection) in the EU was
higher than the combined impact of 31 other infectious dis-
eases under ECDC surveillance [5].
In the USA, it has been estimated that the 5 most impact-
ing HAIs have a cost of 9.8 billion dollars: surgical site infec-
tions, Ventilation-Associated Pneumonia (VAP), Central
Venous Catheter (CVC) associated bloodstream infections,
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C. difficile infections, and UTIs accounting for 33.7, 31.6,
18.9, 15.4 and < 1% of total costs, respectively [6].
In Italy, about 450–700 thousand HAIs occur every
year in hospitalized patients, of which 30% considered
avoidable. Currently, an HAI monitoring system is still
not available at national level, and related data are lim-
ited to prevalence studies [7].
Similarly, antimicrobial use (AMU) and resistance
(AMR) represent a growing threat to global public
health and the sustainability of healthcare services [8].
The spreading of carbapenemase-producing Enterobac-
teriaceae since 2010 is associated with high lethality in
hospital settings [9] and a global alert has been raised by
the World Health Organization (WHO) [10]. A system-
atic review of infections with antibiotic-resistant bacteria
in the EU estimated about 670,000 cases in 2015, of
which 63.5% were associated with healthcare. About 33,
000 deaths and 870,000 DALYs were attributable to
these infections [11].
Italy is one of the European countries with the highest
level of AMU and with the highest prevalence of AMR
both in the community and in hospital settings [12, 13].
In 2015, the project “Good practices for the surveillance
and control of antimicrobial resistance” was funded by
the Italian National Centre for Disease Prevention and
Control (CCM) in order to promote integrated actions
at national level to control AMR [14].
In order to estimate the burden of HAIs and AMR in
the EU, ECDC provided a standardized protocol for HAI
Point Prevalence Survey (PPS) to allow data gathering
and comparison. The first ECDC prevalence study in the
EU was realized in 2011–2012 [2]. A second ECDC
study (PPS2) has been conducted in 2016–2017 [13]. In
Italy, HAI prevalence in PPS2 (2016) resulted equal to
8.0% [13, 15]. The most common infections were pneu-
monia (20.3%), bloodstream infections (18.3), UTI (18%),
surgical site infections (14.4%) and gastrointestinal infec-
tions (8.5%).
In Ferrara University Hospital (FUH), HAI and
AMR monitoring have begun in 1992. In 2011 FUH
has joined ECDC PPS. An internal survey was re-
peated with the same protocol in 2012 and 2013 and
data were published [16]. Subsequently, FUH also
participated in 2016–2017 ECDC PPS. Additionally,
FUH implemented for a long time risk management
and infection control actions, including surveillance of
surgical site infections, UTI and bloodstream infec-
tions, antimicrobial stewardship [17] and an AMR
alert system, retraining of healthcare workers and ap-
plication of WHO Guidelines on hands hygiene [18].
In 2018 a Lean Healthcare Management program for
infection control (Lean4Health) was adopted in FUH,
establishing improvement actions in Rehabilitation
and Surgical departments [19].
The objective of this study was to determine the (1)
prevalence of HAI and associated risk factors, (2) distri-
bution of systemic AMU and AMR trend in FUH, com-
paring prevalence data recorded in 2016 and 2018.
Methods
The point prevalence survey took place from November
14th through 30th of 2016 and from November 12th
through 23rd of 2018 in FUH, a tertiary care hospital in
Northern Italy accounting 658 beds (578 acute-care, 70
rehabilitation, 10 post-acute care).
Study protocol was approved by the Independent Ethical
Committee of Area Vasta Emilia Centrale (CE-AVEC,
study code: 638 t2018/Oss/AOUFe; date of approval CE:
17/10/2018). As no information which may identify the
subjects was collected, no informed consent was obtained.
Both surveys followed the ECDC PPS protocol version
5.3 [20]. In order to eliminate potential sources of con-
flict of interest, under-reporting of HAIs and variability
of results, data were gathered by trained, independent
surveyors (resident doctors of the Postgraduate School
of Hygiene and Preventive Medicine of University of
Ferrara) and one survey leader (Infection Risk Manager
of FUH), consulting clinical documentation and inter-
viewing Medical and Assistant Referents for the manage-
ment of infectious risk in each department.
All inpatients and newborns admitted to the wards be-
fore 8:00 AM and not discharged at the time of the sur-
vey were included as indicated by the ECDC protocol
[20]. Patients admitted to the emergency department
and day surgery were excluded. Data collection in each
ward was completed within the same day.
Data included admission date, patient demographics,
systemic antimicrobial therapy, active HAIs, surgical
procedures (using National Health Safety Network –
NHSN categories [20]) and medical devices presence at
the time of survey or on the HAI onset date (urinary
catheter, CVC, peripheral venous catheter – PVC, mech-
anical ventilation), antimicrobial resistance data when
blood culture was available and patients underlying
medical conditions through McCabe score [21]. McCabe
score is a classification of the severity of patient’s comor-
bidities, including chronic conditions and conditions
impairing immunological system (for example diabetes
requiring amputation or post amputation, end-stage
hematological malignancies, chronic leukemias, meta-
static carcinoma).
Active HAI definition required infection symptoms on
the survey day or systemic antimicrobial treatment on
the survey day for symptoms present previously and to
meet ECDC surveillance criteria for HAI [20]. Antimi-
crobials have been categorized accordingly to the Ana-
tomical Therapeutic Chemical classification (ATC) [22].
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Time at risk is the time in days elapsed from the date
of admission to the date of the survey. It has been cate-
gorized in 0 (0–6 days) and 1 (> 6 days). The cutoff of 6
days has been chosen accordingly to the median time of
hospital stay on survey date resulted in the Italian PPS2
Report 2016/2017 [15].
Statistical analysis
Categorical data were expressed as total numbers and per-
centages. The Shapiro-Wilk test was used to test for normal-
ity of the distribution of the continuous variables. In the
presence of symmetry of the distributions, the variables will
be represented with the mean and Standard Deviation (SD)
or, in the case of non-normal distribution, with the median
value and Interquartile Range [IQR – 1st quartile 3rd quar-
tile]. Statistical comparisons of categorical variables were
assessed using Pearson’s χ2 test or Fisher’s exact test depend-
ing on the minimal expected count in each crosstab.
Unadjusted logistic regression analysis was performed to esti-
mate Odds Ratios (ORs) and respective 95% Confidence In-
tervals (95% CIs). All variables were allowed entry in the
multivariate logistic regression model, including those that
resulted statistically not significant in the univariate analysis.
The final multivariate logistic regression model has been esti-
mated using a backward elimination stepwise procedure with
a significance level of p < 0.05 for a variable to stay in the
model. Model calibration was assessed using the Hosmer-
Lemeshow goodness-of-fit test [23]. Area under the
Receiver-Operating Curve (AROC) was used to assess dis-
crimination power of the model.
Data was recorded with ECDC provided software
HELICSWin.net v.1.3. All analyses were performed using
STATA/SE ver 13.1 (Stata Corporation, College Station,




A total of 1103 patients were included in the two surveys;
1 patient was excluded for incomplete data entry. There-
fore, 1102 patients were included in the final analysis (530
in 2016, 572 in 2018). The demographics and clinical
characteristics of patients are summarized in Table 1. The
median age was 71 [IQR 56 82] years and the median dur-
ation of hospital stay was 7 [IQR 3 15] days.
Of the patients surveyed, 337 (30.5%) underwent at least
one surgical procedure since admission, of which 170
(50.4%) had major surgeries according to ECDC criteria.
Factors associated with HAIs
In the unadjusted analysis patients with worst McCabe
Scores (Ultimately Fatal and Rapidly Fatal disease), that had
CVC, indwelling urinary catheter, mechanically assisted
ventilation or hospitalized for more than 6 days since ad-
mission were at an increased risk of HAI. (Table 1).
Multivariate logistic regression showed that patients
with “Rapidly Fatal” McCabe Scores, who had PVC, CVC,
indwelling urinary catheter or mechanically assisted venti-
lation, or hospitalized for more than 6 days since admis-
sion were at an increased risk of HAI. (Table 1).
Prevalence of HAIs
Overall HAI prevalence was 10.4% (patients with at least
one HAI), 10.0% in 2016 (53 patients) and 11.0% in 2018
(63 patients). In acute-care wards HAI prevalence resulted
9.9% in 2016 (9.2% in medical departments, 7.6% surgical
departments, 35.0% intensive care units) and 11.8% in
2018 (12.4% in medical departments, 6.8% in surgical de-
partments, 36.8% in intensive care units). In rehabilitation
wards prevalence resulted 12.1% in 2016 and 5.8% in
2018. No HAIs were present in post-acute care.
Total count of HAIs resulted 63 in 2016 and 74 in 2018.
Most common infection types in 2016 were: pneumonia
(27.0%), UTI (25.4%), bloodstream infections (15.9%), gastro-
intestinal infections (9.5%), surgical site infections (6.3%) and
clinical sepsis (6.3%). In 2018 were pneumonia (32.4%),
bloodstream infections (21.6%), gastrointestinal infections
(10.8%), surgical site infections (9.5%), UTI (6.8%). 2016–
2018 trends in HAIs resulted statistically significant for UTIs
only (p= 0.003). See Table 2 for complete results.
Antimicrobial use
Four hundred eighty-four inpatients (44.2%) were receiv-
ing at least one antimicrobial drug, 239 (45.0%) in 2016
and 245 (42.8%) in 2018, respectively. Total prescribed
antimicrobial count resulted 348 in 2016 and 345 in
2018. ATC most frequent antimicrobial classes were:
“combinations of penicillins, including beta-lactamase
inhibitors” (27.3% in 2016 and 23.8% in 2018), “third-
generation cephalosporins” (20.7% in 2016 and 22.6% in
2018), “fluoroquinolones” (8.0% in 2016, 7.0% in 2018).
2016–2018 trends in AMU resulted not significant.
(Table 2).
HAI pathogens and antimicrobials resistance
At the time of the surveys, microbiological data were
available for 59 HAI (20 in 2016 and 39 in 2018). Most
frequent pathogens resulted C. difficile (16.9%), K. pneu-
moniae (11.9%), C. albicans (8.5%), E. coli (8.5%) and S.
epidermidis (8.5%), S. aureus (6.8%), S. maltophilia
(6.8%). Of these, 60.0% of E. coli were nonsusceptible to
third-generation cephalosporins. Nonsusceptibility to
third generation cephalosporins and carbapenems was
present in 57.1 and 14.2% of K. pneumoniae, respect-
ively. S. aureus was Oxacillin resistant in 1 case (25.0%).
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Discussion
The main results of this study were that 10.4% of inpa-
tients had at least 1 HAI and 44.2% inpatients was on at
least 1 systemic antimicrobial agent, without any statisti-
cally significant difference observed between 2016 and
2018 surveys. AMU shows a constantly decreasing trend
in FUH surveys (54.4% in 2011, 50.1% in 2012, 48.4% in
2013, 45.0% in 2016, 42.8% in 2018, 16].
The prevalence of HAIs observed in FUH resulted higher
than in other studies conducted in the EU and based on
ECDC protocol. EU corrected HAI prevalence after
validation for PPS2 resulted 6.5% in 2016. In this study, re-
ported HAI prevalence for Italy over a sample of 14,476 pa-
tients was 8.0%, one of the highest values in the EU
countries [13]. However, in PPS2 HAI prevalence was higher
in larger hospital accounting more than 500 beds (9.32%)
and lower in smaller hospitals (5.97%). The proportion of pa-
tients undergoing at least 1 systemic antimicrobial agent was
similar (44.5%) [15]. A multicentric PPS study in Switzerland
observed an HAI prevalence of 5.6% [24]. The first national
PPS in Singapore acute-care hospitals reported similar results
for HAI prevalence (11.9%) and a higher AMU (51.0%) [25].
Table 1 Baseline Characteristics and Risk Factors for Healthcare-Associated Infections
Unadjusted logistic regression Adjusted logistic regression
Patient Characteristics Patients without HAI Patientswith HAI 95% CI 95% CI
n = 987 n = 115 OR lower upper OR lower upper p-value
Sex
female, n (%) 498 (50.5) 57 (49.5) 1.04 0.70 1.52
Age, years
median [IQR] 71 [56 82] 71 [57 82] 1.01 0.99 1.01
Age classes, n (%)
15–64 years 345 (35.0) 39 (33.9) Ref
0–1 years 29 (2.9) 3 (2.6) 0.92 0.27 3.14
2–14 years 15 (1.5) 0 (0.0) – – –
> 64 years 598 (60.6) 73 (63.5) 1.08 0.72 1.63
McCabe Score, n (%)
Non-fatal disease 594 (61.0) 30 (27.0) Ref
Ultimately fatal disease 233 (24.0) 35 (31.5) 2.97 1.78 4.96
Rapidly fatal disease 146 (15.0) 46 (41.5) 6.23 3.80 10.22 2.63 1.59 4.36 0.001
Medical Devices, n (%)
Presence of PVC 674 (68.3) 81 (71.7) 1.18 0.76 1.81 2.80 1.57 4.99 0.001
Presence of urinary catheter 346 (35.2) 73 (64.6) 3.36 2.24 5.05 1.78 1.10 2.90 0.019
Presence of CVC 120 (12.2) 52 (45.2) 5.96 3.94 9.02 3.59 1.98 6.51 < 0.001
Presence of MV 18 (1.8) 17 (14.9) 9.43 4.71 18.90 4.13 1.68 10.19 0.002
Surgery, n (%)
None 688 (69.9) 75 (65.2) Ref
Non-NHSN 148 (15.0) 19 (16.5) 1.18 0.69 2.01
NHSN 149 (15.1) 21 (18.3) 1.29 0.77 2.16
Time at risk*, days
median [IQR] 6 [2 13] 15 [9 29] 1.01 1.003 1.011
Time at risk, n (%)
> 6 days 472 (47.8) 103 (89.6) 9.37 5.08 17.24 9.38 4.87 18.08 < 0.001
Year of the survey, n (%)
2016 478 (48.4) 52 (45.2) Ref
2018 509 (51.6) 63 (54.8) 1.14 0.77 1.68
Abbreviations: HAI Healthcare-Associated Infection, IQR Interquartile Range, PVC Peripheral Vascular Catheter, CVC Central Venous Catheter, MV Mechanical
Ventilation, NHSN National Health Safety Network, OR Odds Ratio, CI Confidence Interval, Ref Reference Category
*Time elapsed from date of admission to date of survey
Model log-likelihood = − 265.84; LR χ2 = 170.8, p < 0.001. Hosmer-Lemeshow χ2 = 6.81, p = 0.4486. Area under receiver operating characteristics curve (AROC) =
0.84. Values in bold are statistically significant (p < 0.05)
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Table 2 Prevalence, clinical setting, infection site of Healthcare-Associated Infections and Antimicrobial Use by year of survey
2016 2018 Total
Total No. of Patients, n (%) 530 (48.1) 572 (51.9) 1102 (100.0)
HAI Prevalence (at least one), n (%)† 52 (9.8) 63 (11.0) 115 (10.4)
Antimicrobials use prevalence (at least one), n (%)† 239 (45.0) 248 (42.8) 487 (44.2)
HAI by clinical setting, n (%)*† 52 63 115
Surgery 9 (17.3) 6 (9.5) 15 (13.0)
Medicine 27 (51.9) 40 (63.5) 67 (58.3)
Geriatrics 0 (0.0) 1 (1.6) 1 (0.9)
Intensive Care 7 (13.5) 7 (11.1) 14 (12.2)
Gynaecology/Obstetrics 0 (0.0) 3 (4.8) 3 (2.6)
Paediatrics/Neonatology 1 (1.9) 2 (3.2) 3 (2.6)
Rehabilitation 8 (1.5) 4 (6.3) 12 (10.4)
Post-acute care 0 (0.0) 0 (0.0) 0 (0.0)
Total No. of HAI 63 74 137
HAI by infection site, n (%)‡
Pneumonia 17 (27.0) 24 (32.4) 41 (29.9)
Bloodstream Infections 10 (15.9) 16 (21.6) 26 (19.0)
Urinary Tract Infections‡ 16 (25.4) 5 (6.8) 21 (15.4)
Gastro-intestinal system infections 6 (9.5) 8 (10.8) 14 (10.2)
Surgical site infections 4 (6.3) 7 (9.5) 11 (8.0)
Clinical sepsis 4 (6.3) 4 (5.4) 8 (5.8)
Infections of ear, nose, throat, larynx and mouth 1 (1.6) 5 (6.8) 6 (4.4)
Cellulitis, wound, deep soft tissue not involving bone, not related to surgery 0 (0.0) 4 (5.4) 4 (2.9)
Lower respiratory tract infections 2 (3.2) 1 (1.4) 3 (2.2)
Others 3 (4.8) 0 (0.0) 3 (2.2)
Total No. of antimicrobials 348 345 693
ATC Antimicrobial classes, n(%)†
J01CR Combinations of penicillins, incl. Beta-lactamase inhibitors 95 (27.3) 82 (23.8) 177 (25.6)
J01DD Third-generation cephalosporins 72 (20.7) 78 (22.6) 150 (21.6)
J01MA Fluorochinolones 28 (8.0) 24 (7.0) 52 (7.5)
J01FA Macrolides 13 (3.7) 20 (5.8) 33 (4.7)
J02 AC Triazole derivatives 15 (4.3) 17 (4.9) 32 (4.6)
J01DH Carbapenems 16 (4.6) 15 (4.3) 31 (4.5)
J01XD Imidazole derivatives 17 (4.9) 14 (4.1) 31 (4.5)
J01XX08 Linezolid 13 (3.7) 16 (4.6) 29 (4.1)
J01XA Glycopeptide antibacterials 12 (3.4) 15 (4.3) 27 (3.8)
J01DB First-generation cephalosporins 11 (3.2) 14 (4.1) 25 (3.6)
J01FF Lincosamides 9 (2.6) 8 (2.3) 17 (2.5)
J01CA Penicillins with extended spectrum 8 (2.3) 7 (2.0) 15 (2.2)
J01GB Aminoglycosides 12 (3.4) 2 (0.6) 14 (2.0)
A07AA Intestinal anti-infectives antibiotics 0 (0.0) 8 (2.3) 8 (1.1)
J01XX09 Daptomycin 3 (0.9) 4 (1.2) 7 (1.0)
Others 24 (6.9) 21 (6.1) 45 (6.5)
Abbreviations: HAI Healthcare-Associated Infection, AMU Antimicrobial Use, ATC Anatomical Therapeutic Chemical Classification. *Percentages have been
calculated on HAI prevalence in 2016 and 2018, respectively
† p-value = not significant; ‡ p-value < 0.05
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As in other studies, intensive care unit was the clinical setting
with higher HAI prevalence (35.0% in 2016 and 36.8% in
2018, 2,15,16,24].
Among all inpatients, factors independently associated
with increased HAI risk were a presence of medical de-
vices (PVC, CVC, indwelling urinary catheter or mech-
anically assisted ventilation) a length of hospital stay of
at least 1 week and a “Rapidly Fatal” McCabe score (ex-
pected fatal outcome within 1 year).
Regarding the type of HAI, pneumonia, bloodstream in-
fections and UTI were the three most frequent consider-
ing both surveys. However, UTI significantly decreased in
2018 (from 25.4 to 6.5%), dropping behind gastrointestinal
system infections and surgical site infections. This could
be explained by the Lean Healthcare Management pro-
gram that was carried out in FUH in 2018, establishing
improvement actions in Rehabilitation and Surgical de-
partments and the update of FUH standard operating pro-
cedure for prevention of catheter-associated urinary tract
infection according to the latest available evidence-based
guidelines [26–29]. In 2019, the Lean Healthcare Manage-
ment program has been extended to prevention and man-
agement of bloodstream infections in all hospital wards,
including the Emergency Department.
The most frequent causative HAI pathogen was C. dif-
ficile (CD). Infections caused by CD represent one of the
5 most financially impacting HAIs [6]. American College
of Gastroenterology “Guidelines for diagnosis, treatment
and prevention of CD infections” report that antibiotics
are the main risk factor for CD infections, particularly
cephalosporin, fluoroquinolones and clindamycin [30].
These three drugs classes represent 30% of all systemic
antimicrobials prescribed in FUH. Studies confirm the
importance of antimicrobial stewardship, pointing out a
reduction in CD infections incidence up to 60% [31–33].
Furthermore, AMR to third-generation cephalosporins
(the second most frequently prescribed systemic anti-
microbial in FUH) was observed in about 60% of Entero-
bacteriaceae and this family of microorganism was the
causative pathogen of 25% of all HAI.
Limitations
These surveys have some limitations. First, our study
considers a large acute-care hospital, therefore results
are not generalizable for smaller hospitals (< 500 pa-
tients). As pointed out in the second Italian PPS, HAI
prevalence may indeed vary greatly with the hospital
number of beds and the case-mix [15]. Second, data on
AMR are limited because only a small proportion of mi-
croorganisms were tested as part of diagnosing.
Conclusions
Results of this study contribute to reinforce the state-
ment that HAI and AMR remain a high burden for
healthcare systems, undermining patient safety in hospi-
tals and causing high rates of morbidity, mortality and
costs [6].
Twenty years since the report To Err is Human [34],
hospitals still need to be made safer, adopting evidence-
based protocols for medical devices management and
strict application of infection control guidelines, espe-
cially for frail patients with short life expectancy and
prolonged hospital stays, in order to prevent HAI, re-
duce AMU and limit AMR.
PPSs represent a fast, easily repeatable, and not expen-
sive method to accomplish HAI and AMU surveillance
in health-care structures, pointing out priority areas that
need improvement actions and providing feedback to
health care professionals. Furthermore, the ECDC PPS
protocol has been used worldwide [25, 35], allowing
comparisons among different studies.
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